Prelude Therapeutics Incorporated (PRLD) investor relations documents from the company's IR site: 2 presentations, 5 press releases; latest deck 2026-04-15. Read in-app with summaries. First-party data.
Beyond Conventional Payloads: Unlocking New Therapeutic Landscapes With Precision Degrader-Antibody Conjugates (DACs): Prelude Therapeutics is developing Precision Degrader-Antibody Conjugates (DACs) to expand oncology treatment options beyond conventional cytotoxic payloads.
| Published | Type | Document |
|---|---|---|
| 2026-04-15 | Presentation | Beyond Conventional Payloads: Unlocking New Therapeutic Landscapes With Precision Degrader-Antibody Conjugates (DACs) |
| 2026-03-15 | Presentation | Discovery of precision degrader antibody conjugates (pDACs) employing novel SMARCA2/4 degrader payloads |
| 2024-07-09 | Press release | Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pemb |
| 2023-03-15 | Press release | Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update |
| 2023-03-15 | Press release | Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubru |
| 2022-11-14 | Press release | Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update |
| Press release | Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
PRLD overview · PRLD earnings · PRLD financials · PRLD KPIs · PRLD ownership · PRLD peers · PRLD filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.